Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients

European Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2015, Pages 43-50

  Gao, Li Chen ^a   Wang, Di ^a   Liu, Fang Qun ^a   Huang, Zheng Yu ^a   Huang, Hong Guang ^a   Wang, Gui Hua ^a   Chen, Xi ^a   Shi, Qun Zhi ^a   Hong, Li ^b   Wu, Li Ping ^b   Tang, Jie ^c  

^a CHANGSHA CENTRAL HOSPITAL   (China)

^b Hunan Province Geriatric Hospital   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Pharmacogenetics

Indexed keywords

LATANOPROST; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 1; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA RECEPTOR; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; ABCC4 PROTEIN, HUMAN; ANTIHYPERTENSIVE AGENT; CYCLOOXYGENASE 1; MULTIDRUG RESISTANCE PROTEIN; PROSTAGLANDIN F; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; PTGS1 PROTEIN, HUMAN;

ADULT; ARTICLE; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOOXYGENASE 1; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN;

EID: 84922088118     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1769-8     Document Type: Article

References (25)

1. (1998) The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. American journal of ophthalmology 126 (4): 498-505
2. Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90(3):262-267. doi:10.1136/bjo.2005.081224
3. Scherer WJ (2002) A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther: Off J Assoc Ocul Pharmacol Ther 18(3):287-291. doi:10.1089/108076802760116205
4. McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA (2008) Intraocular pressure response to topical beta-blockers associated with an ADRB2 single-nucleotide polymorphism. Arch Ophthalmol 126(7):959-963. doi:10.1001/archopht.126.7.959
5. Inagaki Y, Mashima Y, Fuse N, Funayama T, Ohtake Y, Yasuda N, Murakami A, Hotta Y, Fukuchi T, Tsubota K (2006) Polymorphism of beta-adrenergic receptors and susceptibility to open-angle glaucoma. Mol Vis 12:673-680
6. Sakurai M, Higashide T, Ohkubo S, Takeda H, Sugiyama K (2014) Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension. Br J Ophthalmol 98(4):469-473. doi:10.1136/bjophthalmol-2013-304267
7. McCarty CA, Berg R, Patchett R, Wilke RA, Burmester JK (2012) Lack of association between polymorphisms in the prostaglandin F2alpha receptor and solute carrier organic anion transporter family 2A1 genes and intraocular pressure response to prostaglandin analogs. Ophthalmic Genet 33(2):74-76. doi:10.3109/13816810.2011.628357
8. Sakurai M, Higashide T, Takahashi M, Sugiyama K (2007) Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 114(6):1039-1045. doi:10.1016/j.ophtha.2007.03.025
9. Cryan LM, Fitzgerald DJ, O'Brien C (2009) Ocular prostaglandin production and morphology in mice lacking a single isoform of cyclooxygenase. Prostaglandins Leukot Essent Fat Acids 81(5-6): 401-409. doi:10.1016/j.plefa.2009.08.001
10. Neufeld AH, Hernandez MR, Gonzalez M, Geller A (1997) Cyclooxygenase-1 and cyclooxygenase-2 in the human optic nerve head. Exp Eye Res 65(6):739-745. doi:10.1006/exer.1997.0394
11. Motovska Z, Kvasnicka J, Hajkova J, Kala P, Simek S, Bobcikova P, Petr R, Bilkova D, Poloczek M, Miklik R, Fischerova M, Maly M, Widimsky P (2010) Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trial. Atherosclerosis 212(2):548-552. doi:10.1016/j.atherosclerosis.2010.07.006
12. Pattabiraman PP, Pecen PE, Rao PV (2013) MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure. Invest Ophthalmol Vis Sci 54(3):1636-1649. doi:10.1167/iovs.12-11107
13. Zhu P, Zhu Q, Zhang Y, Ma X, Li Z, Li J, Chen J, Luo L, Ring HZ, Ring BZ, Su L (2013) ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort. PLoS One 8(1):e55197. doi:10.1371/journal.pone.0055197
14. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, Potter JD (2002) Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 20(5):409-410. doi:10.1002/humu.9080
15. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL (2008) The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. The J Pharmacol Exp Ther 325(3):859-868. doi:10.1124/jpet.108.136523
16. Kawaguchi I, Higashide T, Ohkubo S, Kawaguchi C, Sugiyama K (2012) Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects. Jpn J Ophthalmol 56(4):346-353. doi:10.1007/s10384-012-0155-2
17. Wakabayashi Y, Higashide T, Sugiyama K (2011) Improved prediction of fellow-eye response in one-eye trials using multiple intraocular pressure measurements. Jpn J Ophthalmol 55(5):480-485. doi:10.1007/s10384-011-0054-y
18. Stjernschantz J, Selen G, Sjoquist B, Resul B (1995) Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res 23:513-518
19. Toris CB, Camras CB, Yablonski ME (1993) Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 100(9):1297-1304
20. Ang A, Reddy MA, Shepstone L, Broadway DC (2004) Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol 88(5):630-634
21. Tamada Y, Taniguchi T, Murase H, Yamamoto T, Kitazawa Y (2001) Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther: Off J Assoc Ocul Pharmacol Ther 17(1):19-25. doi:10.1089/108076801750125612
22. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, Crean P, Shields DC, Fitzgerald DJ (2005) Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost: JTH 3(10):2340-2345. doi:10.1111/j.1538-7836.2005.01555.x
23. Lee CR, Bottone FG Jr, Krahn JM, Li L, Mohrenweiser HW, Cook ME, Petrovich RM, Bell DA, Eling TE, Zeldin DC (2007) Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 17(2):145-160. doi:10.1097/01.fpc.0000236340.87540.e3
24. Kraft ME, Glaeser H, Mandery K, Konig J, Auge D, Fromm MF, Schlotzer-Schrehardt U, Welge-Lussen U, Kruse FE, Zolk O (2010) The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci 51(5):2504-2511. doi:10.1167/iovs.09-4290
25. Verschuren JJ, Boden H, Wessels JA, van der Hoeven BL, Trompet S, Heijmans BT, Putter H, Guchelaar HJ, Schalij MJ, Jukema JW (2013) Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevationmyocardial infarction. Int J Cardiol 167(6):2882-2888. doi:10.1016/j.ijcard.2012.07.020